WO2019075583A1 - Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer - Google Patents
Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer Download PDFInfo
- Publication number
- WO2019075583A1 WO2019075583A1 PCT/CA2018/051336 CA2018051336W WO2019075583A1 WO 2019075583 A1 WO2019075583 A1 WO 2019075583A1 CA 2018051336 W CA2018051336 W CA 2018051336W WO 2019075583 A1 WO2019075583 A1 WO 2019075583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- psma
- cancer
- derivative
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Definitions
- PSMA Prostate specific membrane antigen
- the common radiolabeled PSMA-targeting endoradiotherapeutic agents are derivatives of lysine-urea-glutamate (Lys-urea-Glu) including 131 I-MIP-1095, 177 Lu-PSMA-617 and 177 Lu-PSMA l&T. 5"7 Among them, 177 Lu-PSMA-617 is the most studied agent, and is currently being evaluated in multi- center trials. 7"14 Preliminary data demonstrated that 177 Lu-PSMA-617 was effective in treating metastatic prostate cancer with 32 - 60% of patients having > 50% reduction in PSA levels, and without severe side effects. 7"13 In a phase 2 Australian study, an objective response was observed in 82% of patients with measurable nodal or visceral disease.
- 225 Ac-PSMA-617 for endoradiotherapy, the supply of 225 Ac is globally limited. More effective 177 Lu-labeled PSMA-targeting agents will have a greater immediate impact for endoradiotherapy of prostate cancer than 225 Ac-PSMA-617 as good manufacturing practice (GMP) compliant 177 Lu is commercially available in larger quantities from multiple suppliers.
- GMP manufacturing practice
- the greater efficacy of 225 Ac-PSMA-617 may be due to the high linear energy transfer of a-particles, which causes double strand breaks that may be less susceptible to radiation resistance compared to the indirect damage produced by ⁇ -particles emitted by 177 Lu.
- One approach to increase the radiotherapeutic efficacy is to increase the radiation dose deposited in tumors per unit administered radioactivity of the 177 Lu-labeled agents. Improving the delivery of 177 Lu to tumors can also reduce the cost of therapeutic radiopharmaceuticals by decreasing radioisotope costs.
- This disclosure provides a compound which is of Formula l-a or Formula l-b, or is a salt or solvate of Formula l-a or Formula l-b:
- L is -CH2NH-, -(CH 2 ) 2 NH- -(CH 2 ) 3 NH- or -(CH 2 ) 4 NH-;
- R 4 is a radiometal chelator optionally bound by radiometal X; and n is 1-3.
- X when X is a diagnostic radiometal (e.g. suitable for imaging, such as but not necessarily limited to 6 Cu, 111 In, 89 Zr, Sc, 68 Ga, 99m Tc, 86 Y, 152 Tb or 155 Tb), such compounds may be used for imaging PSMA-expressing cancer in a subject. Accordingly, there is also disclosed a method of imaging PSMA-expressing cancer in a subject, the method comprising: administering to the subject a composition comprising the compound and a pharmaceutically acceptable excipient; and imaging tissue of the subject. [0010] In some embodiments, when X is a therapeutic radiometal (e.g.
- a toxic radiometal such as but not limited to 64 Cu, 67 Cu, 90 Y, 111 ln, 114m ln, 117m Sn, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 225 Ac, 213 Bi, 224 Ra, 212 Bi, 212 Pb, 225 Ac, 227 Th, 223 Ra, 7 Sc, 186 Re or 188 Re), such compounds may be used for treating PSMA- expressing cancer in a subject.
- a method of treating prostate specific membrane antigen (PSMA)-expressing cancer in a subject comprising: administering to the subject a composition comprising the compound and a pharmaceutically acceptable excipient.
- FIGURE 2 shows SPECT/CT images of (A) 177 Lu-labeled PSMA-617 and (B) HTK01169 in mice bearing LNCaP tumor xenografts. Higher and sustained uptake of 177 Lu-HTK01169 in tumor xenografts was observed.
- FIGURE 3A is a graph showing biodistribution of 177 Lu-PSMA-617 for selected organs in mice bearing LNCaP tumor xenografts (n ⁇ 5). Bars organized left to right: 1 h, 4 h, 24 h, 72 h and 120h.
- FIGURE 5 is a graph showing radiation doses (mGy/MBq) of 177 Lu-PSMA-617 (lower) and
- 177 Lu-HTK01 169 (upper) to LNCaP tumors calculated using the OLINDA software. These data were obtained with various tumor masses but assuming same tumor uptake (%ID, percent injected dose) and residence time for 177 Lu-PSMA-617 and 177 Lu-HTK01169.
- FIGURE 10 shows lines graphs of changes of (A) tumor volume and (B) body weight over time after mice were treated with 177 Lu-HTK01169 (9.3 MBq).
- FIGURE 14 shows maximum intensity projection PET/CT images of 68 Ga-HTK03055, 68 Ga- HTK03056, and 68 Ga-HTK03058 acquired at 1 h and 3h post-injection in mice bearing LNCaP tumor xenografts. All three compounds show some extent of blood retention as heart is clearly visualized in images at 1 h post-injection.
- the terms “comprising,” “having”, “including” and “containing,” and grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and/or method steps.
- the term “consisting essentially of” if used herein in connection with a composition, use or method, denotes that additional elements and/or method steps may be present, but that these additions do not materially affect the manner in which the recited composition, method or use functions.
- the term “consisting of” if used herein in connection with a composition, use or method excludes the presence of additional elements and/or method steps.
- the terms “treat”, “treatment”, “therapeutic” and the like includes ameliorating symptoms, reducing disease progression, improving prognosis and reducing cancer recurrence.
- the term "diagnostic agent” includes an "imaging agent”.
- a “diagnostic radiometal” includes radiometals that are suitable for use as imaging agents.
- the term "subject” refers to an animal (e.g. a mammal or a non-mammal animal).
- the subject may be a human or a non-human primate.
- the subject may be a laboratory mammal (e.g., mouse, rat, rabbit, hamster and the like).
- the subject may be an agricultural animal (e.g., equine, ovine, bovine, porcine, camelid and the like) or a domestic animal (e.g., canine, feline and the like).
- salts and solvate have their usual meaning in chemistry.
- the compound when it is a salt or solvate, it is associated with a suitable counter-ion.
- a suitable counter-ion It is well known in the art how to prepare salts or to exchange counter-ions.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of a suitable base (e.g. without limitation, Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are generally carried out in water or in an organic solvent, or in a mixture of the two.
- Counter-ions may be changed, for example, by ion-exchange techniques such as ion-exchange chromatography. All zwitterions, salts, solvates and counter-ions are intended, unless a particular form is specifically indicated.
- the salt or counter-ion may be pharmaceutically acceptable, for administration to a subject.
- suitable excipients include any suitable buffers, stabilizing agents, salts, antioxidants, complexing agents, tonicity agents, cryoprotectants, lyoprotectants, suspending agents, emulsifying agents, antimicrobial agents, preservatives, chelating agents, binding agents, surfactants, wetting agents, non-aqueous vehicles such as fixed oils, or polymers for sustained or controlled release. See, for example, Berge et al. 1977. (J. Pharm Sci.
- R 4 is a radiometal chelator optionally bound by radiometal X; and n is 1-3.
- the wavy line " ⁇ " symbol shown through a bond in a chemical formula is intended to define the R group (e.g. R 1 , R 2 and R 3 ) on one side of the wavy line, without modifying the definition of the structure on the opposite side of the wavy line.
- R group e.g. R 1 , R 2 and R 3
- the atoms outside the wavy lines are include to clarify orientation of the R group. As such, only the atoms between the two wavy lines constitute the definition of the R group.
- the compound is of Formula l-a or is a salt or solvate of Formula l-a.
- the compound is of Formula l-b or is a salt or solvate of Formula l-b.
- R 1 forms the side chain of an amino acid residue (e.g. 2-naphthylalanine etc.).
- an amino acid residue e.g. 2-naphthylalanine etc.
- this amino acid is an L-amino acid, i.e. ""TM (e.g. L-2-naphthylalanine etc.).
- ""TM e.g. L-2-naphthylalanine etc.
- the amino acid is a D-amino acid ⁇ (e.g. D-2-naphthylalanine etc.).
- R 2 may be in para, meta or ortho position on the benzene ring, i.e.: [0047] In some embodiments, R 2 is in para position. In some embodiments, R 2 is in meta position. In some embodiments, R 2 is in ortho position.
- R 3 is 0 (i.e. a Gly residue).
- R 3 is O (i.e. an Asp residue). In some embodiments, the
- Asp residue is D-Asp. In some embodiments, the Asp is L-Asp.
- R 3 is (i.e. a Glu residue). In some embodiments, the
- Glu residue is D-Glu. In some embodiments, the Glu residue is L-Glu.
- R 3 is
- R 3 is
- DOTA (l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid) or a derivative thereof, such as but not limited to DOTAGA; TETA (l,4,8,ll-tetraazacyclotetradecane-l,4,8,ll-tetraacetic acid) or a derivative thereof, such as but not limited to CB-TE2A (4,ll-bis-(carboxymethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]- hexadecane);
- NOTA l,4,7-triazacyclononane-l,4,7-triacetic acid
- NODAGA a derivative thereof, such as but not limited to NODAGA
- TRAP (l,4,7-triazacyclononane-l,4,7-tris[methyl(2-carboxyethyl)phosphinic acid) or a derivative thereof;
- HBED N,N0-bis(2-hydroxybenzyl)-ethylenediamine-N,N0-diacetic acid
- PCTA (3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-l(15),ll,13-triene-3,6,9,-triacetic acid) or a derivative thereof;
- DFO deferrioxamine
- DFO-star tetrahydroxamate DFO*
- OCTAPA N,N0-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N0-diacetic acid
- a derivative thereof e.g. picolinic acid derivatives
- H2-MACROPA N,N'-bis[(6-carboxy-2-pyridil)methyl]-4,13-diaza-18-crown-6) or a derivative thereof.
- X is absent.
- X is a therapeutic radiometal.
- X may be 6 Cu, 67 Cu, 90 Y, 111 ln, 11 m ln, 117m Sn, 153 Sm, 1 9 Tb, 161 Tb, 177 Lu, 225 Ac, 213 Bi, 22 Ra, 212 Bi, 212 Pb, 225 Ac, 227 Th, 223 Ra, 7 Sc, 186 Re, or 188 Re.
- X is 6 Cu.
- X is 67 Cu.
- X is 90 Y.
- X is 111 In.
- X is 11 m ln.
- X is 117m Sn. In some embodiments, X is 153 Sm. In some embodiments, X is 1 9 Tb. In some embodiments, X is 161 Tb. In some embodiments, X is 177 Lu. In some embodiments, X is 225 Ac. In some embodiments, X is 213 Bi. In some embodiments, X is 22 Ra. In some embodiments, X is 212 Bi. In some embodiments, X is 212 Pb. In some embodiments, X is 225 Ac. In some embodiments, X is 227Th . In some embodiments, X is 223 Ra. In some
- X is 7 Sc. In some embodiments, X is 186 Re. In some embodiments, X is 188 Re.
- X is a diagnostic radiometal.
- X may be 6 Cu, 111 ln, 89 Zr, Sc, 68 Ga, 99m Tc, 86 Y, 152 Tb or 155 Tb.
- X is 6 Cu.
- X is 111 ln.
- X is 89 Zr.
- X is Sc.
- X is 68 Ga.
- X is 99m Tc.
- X is 86 Y.
- X is 152 Tb.
- X is 155 Tb.
- R 1 is wherein R 2 is I, Br, F, CI, H, OH, OCH 3 , NH 2 , N0 2 or CH 3 , and wherein X is absent, 90 Y, 67 Ga, 68 Ga, 177 Lu, 225 Ac, or 111 ln. In certain of these embodiments, R 2 is in para position. In certain of these embodiments, R 2 is I. In certain of these embodiments, X is 177 Lu, and in other embodiments, X is 225 Ac.
- R 1 is , wherein R 2 is I, Br, F, CI, H, OH, OCH3, NH2, N0 2 or CH 3 , and wherein X is absent, 90 Y, 67 Ga, 68 Ga, 177 Lu, 225 Ac, or 111 ln.
- R 2 is in para position.
- R 2 is I.
- X is 177 Lu, and in other embodiments, X is 225 Ac.
- n is 3.
- L is -CH2IMH-. In some embodiments, L is -(CH2)2NH- In some embodiments, L is -(CH2)3NH- In some embodiments, L is -(CH2) NH-
- L forms the side chain of an amino acid residue (e.g. 2,3-diaminopropionic acid (Dap), 2,4- diaminobutanoic acid (Dab), ornithine (Orn) or lysine (Lys)).
- this amino acid is an L-amino acid, i.e. .g. L-Dap, L-Dab, L-Orn or L-Lys).
- the amino acid residue e.g. 2,3-diaminopropionic acid (Dap), 2,4- diaminobutanoic acid (Dab), ornithine (Orn) or lysine (Lys)
- this amino acid is an L-amino acid, i.e. .g. L-Dap, L-Dab, L-Orn or L-Lys).
- the amino acid residue e.g. 2,3-diaminopropionic acid (Dap), 2,
- D-amino ac id e.g. D-Dap, D-Dab, D-Orn or D-Lys.
- the amino acid residue formed by L is an L-amino acid and the amino acid residue formed by R 1 is also an L-amino acid. In some embodiments, the amino acid residue formed by L is a D-amino acid and the amino acid residue formed by R 1 is also a D-amino acid. In some embodiments, the amino acid residue formed by L is an L-amino acid and the amino acid residue formed by R 1 is a D-amino acid. In some embodiments, the amino acid residue formed by L is a D- amino acid and the amino acid residue formed by R 1 is an L-amino acid.
- the compound has Formula II or is a salt or solvate of Formula II:
- R 2 is I, Br or methyl; n is 1-3; and X is absent, 225 Ac or 177 Lu.
- R 2 is I. In some of these embodiments, R 2 is Br. In some of these embodiments, R 2 is methyl.
- n is 1. In some of these embodiments, n is 2. In some of these embodiments, n is 3. In some of these embodiments, X is absent. In some of these embodiments, X is 177 Lu and is bound in the DOTA group. In some of these embodiments, X is 225 Ac and is bound in the DOTA group. [0065] In some embodiments, the compound has Formula III or is a salt or solvate of Formula III:
- Example 1 A synthetic scheme for HTK01169 and Lu-HTK01169 is provided in Example 1 below.
- Example 2 provides synthetic schemes for preparing a number of metal-chelating PSMA-binding compounds which incorporate many of the options for the R groups of Formulas l-a and l-b.
- the above compounds modulate albumin-binding and PSMA-binding (e.g. as compared to Lu- PSMA-617) to modulate (e.g. enhance) tumor uptake/retention, so as to provide alternative or improved diagnostic or therapeutic agents for PSMA-expressing cancers.
- albumin-binding and PSMA-binding e.g. as compared to Lu- PSMA-617) to modulate (e.g. enhance) tumor uptake/retention, so as to provide alternative or improved diagnostic or therapeutic agents for PSMA-expressing cancers.
- the above compounds modulate albumin-binding and PSMA-binding (e.g. as compared to Lu- PSMA-617) to modulate (e.g. enhance) tumor uptake/
- an albumin-binding domain i.e. (e.g. iodophenylbutyryl group in Lu-HTK01 169; see also PCT Patent Publication No. WO 2008/053360), which increases blood circulation time of the compound.
- a compound with too strong binding to albumin i.e. too high binding affinity to albumin
- albumin binding affinity is too weak, the compound will clear from blood circulation too fast, reducing the chance to accumulate in the tumor.
- the above compounds also comprise a Lys-ureido-Glu PSMA-binding moeity.
- the PSMA-binding strength of the compound can be modulated (increased or decreased) by modifying R 1 .
- PSMA expression has been detected in various cancers (e.g. Rowe et al., 2015, Annals of Nuclear Medicine 29:877-882; Sathekge et al., 2015, Eur J Nucl Med Mol Imaging 42: 1482-1483; Verburg et al., 2015, Eur J Nucl Med Mol Imaging 42: 1622-1623; and Pyka et al., J Nucl Med November 19, 2015jnumed.115.164442).
- the PSMA-expressing cancer may be prostate cancer, renal cancer, breast cancer, thyroid cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, lung cancer, liver cancer, brain tumor, melanoma, neuroendocrine tumor, ovarian cancer or sarcoma.
- the cancer is prostate cancer.
- the radio-HPLC system was equipped with a Bioscan (Washington, DC) Nal scintillation detector.
- the HPLC columns used were a Phenomenex (Torrance, CA) semi-preparative column (Luna C18, 5 ⁇ , 250 ⁇ 10 mm) and a Phenomenex analytical column (Luna C18, 5 ⁇ , 250 ⁇ 4.6 mm). Radioactivity of 177 Lu-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC ® -25R/W dose calibrator.
- Fmoc-Lys(ivDde)-OH was coupled to the sequence after Fmoc-tranexamic acid. Elongation was continued with the addition of Fmoc-Glu(tBu)-OH and 4-(p- iodophenyl)butyric acid to the /V-terminus. Subsequently, the ivDde-protecting group was removed with 2% hydrazine in DMF, and DOTA-tris(f-bu)ester was coupled to the Lys side chain.
- the yield of HTK01169 was 21 %.
- ESI-MS calculated [M+H] + for HTK01 169 C70H100N12O211 1571.6; found [M+H] + 1571.7.
- Non-specific binding was determined in the presence of 10 ⁇ non-radiolabeled DCFPyL.
- the assay mixtures were further incubated for 1 h at 37 °C with gentle agitation. Then, the buffer and hot ligand were removed, and cells were washed twice with cold HEPES buffered saline. To harvest the cells, 400 ⁇ _ of 0.25 % trypsin solution was added to each well. Radioactivity was measured on a PerkinElmer (Waltham, MA) Wizard2 2480 automatic gamma counter. Nonlinear regression analyses and Ki calculations were performed using the GraphPad Prism 7 software.
- 177 LuCI 3 (329.3 - 769.9 MBq in 10 - 20 ⁇ _) was added to a solution of PSMA-617 or HTK01 169 (25 ⁇ g) in NaOAc buffer (0.5 ml_, 0.1 M, pH 4.5). The mixture was incubated at 90 °C for 15 min, and then purified by HPLC.
- the HPLC purification conditions (semi-prep column, 4.5 mL/min) for 177 Lu- PSMA-617 and 177 Lu-HTK01 169 were 23% and 36% acetonitrile in water (0.1 % TFA), respectively.
- the retention times for 177 Lu- PSMA-617 and 177 Lu-HTK01 169 were 15.0 min and 13.8 min, respectively. Quality control was performed on the analytical column with a flow rate of 2 mL/min using the corresponding purification solvent conditions. The retention times for 177 Lu-PSMA-617 and ' '"LuHTK01169 were both around 5.5 min.
- Plasma protein binding assays were performed according to literature methods. 19 Briefly, 37 kBq of 177 Lu-PSMA-617 or 177 Lu-HTK01 169 in 50 ⁇ PBS was added into 200 ⁇ human serum and the mixture was incubated at room temperature for 1 min. The mixture was then loaded onto a membrane filter (Nanosep®, 30 K, Pall Corporation, USA) and centrifuged for 45 min (30, 130 ⁇ g). Saline (50 ⁇ ) was added and centrifugation was continued for another 15 min. The top part with the membrane filter and the bottom part with the solution were counted on a gamma counter. For control, saline was used in place of human serum.
- a membrane filter Nanosep®, 30 K, Pall Corporation, USA
- mice were anesthetized by inhalation with 2% isoflurane in oxygen, and implanted subcutaneously with 1 ⁇ 10 7 LNCaP cells posterior to the left shoulder. Mice were used for studies when the tumor reached 5-8 mm in diameter 5-6 weeks after inoculation.
- SPECT/CT imaging experiments were conducted using the Ml Labs (Utrecht, the Netherlands) U-SPECT-II/CT scanner. Each tumor-bearing mouse was injected with -37 MBq of 177 Lu-labeled PSMA-617 or HTK01 169 through the tail vein under anesthesia (2% isoflurane in oxygen). The mice were allowed to recover and roam freely in their cage and imaged at 4, 24, 72 and 120 hours after injection. At each time point, the mice were sedated again and positioned in the scanner.
- a 5-min CT scan was conducted first for anatomical reference with a voltage setting at 60 kV and current at 615 ⁇ followed by a 60-min static emission scan acquired in list mode using an ultra-high resolution multi- pinhole rat-mouse (1 mm pinhole size) collimator.
- Data were reconstructed using the U-SPECT II software with a 20% window width on three energy windows.
- the photopeak window was centered at 208 keV, with lower scatter and upper scatter windows centered at 170 and 255 keV, respectively.
- the images were reconstructed using the ordered subset expectation maximization algorithm (3 iterations, 16 subsets), and a 0.5 mm post-processing Gaussian filter. Images were decay corrected to injection time in PMOD (PMOD Technologies, Switzerland) then converted to DICOM for qualitative visualization in the Inveon Research Workplace software (Siemens Medical Solutions USA, Inc.).
- mice were injected with 177 Lu-labeled PSMA-617 or HTK01 169 (2-4 MBq) as described above. At predetermined time points (1 , 4, 24, 72, or 120 h post-injection), the mice were euthanized by CO2 inhalation. Blood was withdrawn immediately from the heart, and the organs/tissues of interest were collected. The collected organs/tissues were weighed and counted using an automated gamma counter. For the blocking study, mice were co-injected with 177 Lu- HTK01169 (2-4 MBq) and 50 nmol of the non-radioactive standard, and organs/tissues of interest were collected at 4 h post-injection.
- Tumor size and body weight were measured twice a week from the date of injection (Day 0) until completion of the study (Day 120). Endpoint criteria were defined as > 20% weight loss, tumor volume > 1000 mm 3 , or active ulceration of the tumor.
- the biodistribution data (available in the Tables 1 and 2, below) was used to determine the kinetics input values required by OLI NDA. First, each of the values was decayed to its corresponding time point (the values on the table are shown at injection time). Then the different time-points of the uptake data (%ID/g) for each organ were fitted to both mono-exponential ( ⁇ - - ae ⁇ bt ) and bi-
- m or gan is the mass of the organ and M represents the total body mass.
- the subscripts indicate whether the values correspond to human or mouse.
- Masses for the organs and total body weight were taken from the simulated masses of the phantoms in OLINDA. As the biodistribution data does not differentiate between left colon, right colon, and rectum that are present in the OLI NDA human phantom, it was assumed that these three regions of the intestine have the same activity uptake (%ID/g) as the large intestine of the biodistribution. The %ID/g of the blood was assumed to be the one for the heart contents of the phantom.
- This value was also used to calculate the bone marrow uptake based on the method described by Wessels et al. 42 in which we assumed a hematocrit fraction of 0.40 based on the patient values shown on that study. At the end, red marrow values used the blood measurements scaled by a factor of 0.32.
- the fat, muscle, and seminal vesicles that are present in the biodistribution data are not modelled in the phantom so the numbers of decays present in these regions were included in the remainder of the body.
- the data was again fitted as for the mouse case and the values for the total number of decays in units of MBqxh/MBq were inputted in OLINDA.
- PSMA-617 and HTK01 169 were synthesized in 25 and 21 % yields, respectively. After reacting with LuC followed by HPLC purification, Lu-PSMA-617 and Lu-HTK01169 were obtained in 62 and 31 % yields, respectively. The identities of PSMA-617, HTK01 169 and their Lu complexes were confirmed by MS analyses.
- 177 Lu labeling was conducted in acetate buffer (pH 4.5) at 90 °C followed by HPLC purification.
- Lu-PSMA-617 and Lu-HTK01169 inhibited the binding of 18 F-DCFPyL to PSMA on
- Table 1 Biodistribution data of 177 Lu-PSMA-617 in mice bearing LNCaP xenografts.
- Table 2 Biodistribution data of 177 Lu-HTK01169 in mice bearing LNCaP xenografts.
- Lu-PSMA-617 cleared rapidly from blood and nontarget organs/tissues. At 1 h post- injection, there was only 0.68 ⁇ 0.23 %ID/g left in blood. Uptake was observed in PSMA-expressing tissues including spleen (3.34 ⁇ 1.77 %ID/g), adrenal glands (4.88 ⁇ 2.41 %ID/g), kidneys (97.2 ⁇ 19.4 %ID/g), lung (1.34 ⁇ 0.39 %ID/g) and LNCaP tumors (15.1 ⁇ 5.58 %ID/g). 20 - 21 The tumor uptake decreased gradually to 7.91 ⁇ 2.82 %ID/g at 120 h post-injection. Due to faster clearance from other tissues/organs, the tumor-to-background contrast ratios of 177 Lu-PSMA-617 improved overtime (Table 1 , above).
- the tumor-to-background contrast ratios of 177 Lu-PSMA-617 improved over time as well, due to sustained uptake in tumor and relatively faster clearance from other organs/tissues.
- blocking with the cold standard reduced uptake in all collected tissues/organs especially the PSMA-expressing kidneys (125 ⁇ 16.4 vs 5.50 ⁇ 1.95 %ID/g) and LNCaP tumors (55.9 ⁇ 12.5 vs 1.70 ⁇ 0.28 %ID/g).
- Table 4 Radiation doses (mGy/GBq) calculated for the major organs of humans (male) using the OLINDA software.
- mice [00119] The results of the endoradiotherapy study are shown in Table 6 and Figure 6, and the changes of LNCaP tumor volume and mouse body weight over time after treatment are shown in Figures 7-12.
- the tumor volume of the control group (Group A in Table 6, Figure 7(A)) increased continuously after treatment (saline injection), and the median survival of the control group was only 14 days (mice were euthanized when their tumor volume reached 1000 mm 3 ).
- the tumors in mice treated with 177 Lu-PSMA-617 (18.5 MBq, Group B in Table 6, Figure 8A) shrank initially but grew back later, leading to an improved median survival of 58 days.
- mice treated with 177 Lu-PSMA-617 or 177 Lu- PSMA-ALB-056 showed extended median survival when compared with the mice in the control group treated with saline. Most importantly, using only 2 MBq of 177 Lu-PSMA-ALB-056 was able to produce slightly better median survival when compared to that from using 5 MBq of 177 Lu-PSMA-617 (36 vs 32 days).
- the carboxylic group at the Glu side chain can be used for binding to albumin, and the a-carboxylic group was used for conjugation to the peptide via solid phase synthesis.
- modification of the linker between the DOTA chelator and the PSMA-targeting Lys-urea-Glu did not adversely affect therapeutic efficacy, which confirms reports that such linker modifications can be well tolerated. 17
- Lu-HTK01 169 was observed to have a 6-fold improvement in PSMA binding compared to Lu-PSMA-617 (Ki values: 0.04 ⁇ 0.01 vs 0.24 ⁇ 0.06 nM).
- the improved PSMA binding may be due to the introduction of the highly lipophilic 4-(p-iodophenyl)butyryl group.
- 177 Lu-HTK01 169 not only showed improved peaked tumor uptake ( 177 Lu-HTK01169: 55.9 ⁇ 12.5 %ID/g; 177 Lu-PSMA-617: 15.1 ⁇ 5.58 %ID/g), but most importantly the uptake was sustained, rather than decreasing over time like 177 Lu-PSMA-617. Without wishing to be bound by theory, this could be due to, in part, the improved PSMA binding of Lu-HTK01169 over Lu-PSMA-617. Compared with 177 Lu-PSMA-617, improved uptake combined with longer residence time provided an 8.3- fold higher radiation dose of 177 Lu-PSMA-617 to LNCaP tumor xenografts.
- Such design strategy may be even more significant for radioisotopes with a longer half-life such as the a-emitter 225 Ac ( 225 Ac, 9.95 d; 177 Lu, 6.65 d).
- 225 Ac a-emitter
- Currently the clinically used 225 Ac is extracted from 229 Th, and is in limited supply.
- 30"31 Switching from 225 Ac-PSMA-617 to 225 Ac- HTK01169 may significantly increase the number of patients who can be treated with 225 Ac-labeled PSMA-targeting radioligands.
- This example showed a quick reduction in size of LNCaP tumor xenografts over time with the injection of -37 MBq of either 177 Lu-PSMA-617 or 177 Lu-HTK01 169 ( Figure 2).
- the -37 MBq injected radioactivity used for the acquisition of high-resolution SPECT images could have exceeded the dose of 177 Lu-HTK01169 needed to treat LNCaP tumors.
- the endoradiotherapy study in this Example compared the median survivals of mice treated with 18.5 MBq of 177 Lu-PSMA-617 or 177 Lu-HTK01 169, as well as with only one half (9.3 MBq), one quarter (4.6 MBq) or one-eighth (2.3 MBq) dose of 177 Lu-HTK01 169.
- the one-eighth dose (2.3 MBq) of 177 Lu-HTK01169 did not produce similar median survival when compared to that of 177 Lu-HTK01 169 (18.5 MBq, Table 6) as predicted from the dosimetry data.
- mice treated with one quarter dose (4.5 MBq) of 177 Lu-HTK01169 was slightly better than that of mice treated with 18.5 MBq of 177 Lu-PSMA-617 (61 vs 58 days, Table 6).
- 177 Lu-PSMA-ALB-056 has been evaluated in a radiotherapy study and compared directly with 177 Lu-PSMA-617. 27 There are two main differences between the findings of this Example and those reported for 177 Lu-PSMA-ALB-056, reported by Umbricht et al.
- this Example used LNCaP, an unmodified endogenous prostate cancer cell line.
- the evaluation of 177 Lu- PSMA-ALB-056 used PC-3 PIP, a transduced cell line with a much higher PSMA expression level than LNCaP cells. 27 Consequently, the treatment doses (2 and 5 MBq) of 177 Lu-PSMA-ALB-056 and 177 Lu- PSMA-617 in the previously reported study were lower than those used in this Example (2.3 - 18.5 MBq).
- the second difference is the size of tumors.
- the range of tumor sizes in the present Example when treatment began with 177 Lu-PSMA-617 or 177 Lu-HTK01 169 was 531 - 640 mm 3 .
- the larger tumors in this Example likely conferred a higher degree of resistance to the treatment, and subsequently required a higher radiation dose to achieve the similar growth inhibition.
- the newly introduced albumin binder in HTK01169 can be constructed directly on solid phase along peptide elongation. Based on promising data obtained from 177 Lu-HTK01 169, this new albumin-binding motif could potentially be applied to other (radio)peptides to extend their blood retention times and maximize therapeutic efficacy.
- EXAMPLE 2 Modified metal-chelating PSMA-binding compounds [00131] 2.1 MATERIALS AND METHODS
- HPLC columns used were a semi-preparative column (Luna C18, 5 ⁇ , 250 x 10 mm) and an analytical column (Luna C18, 5 ⁇ , 250 ⁇ 4.6 mm) purchased from Phenomenex (Torrance, CA).
- the collected HPLC eluates containing the desired peptide were lyophilized using a Labconco (Kansas City, MO) FreeZone 4.5 Plus freeze-drier.
- Mass analyses were performed using an AB SCI EX (Framingham, MA) 4000 QTRAP mass spectrometer system with an ESI ion source.
- C18 Sep-Pak cartridges (1 cm 3 , 50 mg) were obtained from Waters (Milford, MA).
- 68 Ga was eluted from an iThemba Labs (Somerset West, South Africa) generator, and was purified using a DGA resin column from Eichrom Technologies LLC (Lisle, IL). Radioactivity of 68 Ga-labeled peptides was measured using a Capintec (Ramsey, NJ) CRC ® -25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Perkin Elmer (Waltham, MA) Wzard22480 automatic gamma counter.
- Fmoc-2-Aoc-OH (for HTK03026), Fmoc-Ala(2-Anth)-OH (for HTK03027), Fmoc-Ala(1- Pyrenyl)-OH (for HTK03029) or Fmoc-Ala(9-Anth)-OH (for HTK03041) was then coupled to the side chain of Lys using Fmoc-protected amino acid (3 eq.), HBTU (3 eq.), HOBT (3 eq.) and N,N- diisopropylethylamine (8 eq.).
- DOTA-tris(f-bu)ester (2-(4,7, 10-tris(2-(f-butoxy)-2-oxoehtyl)-1 ,4,7, 10)- tetraazacyclododecan-1-yl)acetic acid).
- the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 trifluoroacetic acid (TFA)/triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the semi-preparative column. The eluates containing the desired peptide were collected, pooled, and lyophilized. For HTK03026, the HPLC conditions were 27% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.7 min.
- ESI-MS calculated [M+H] + for HTK03029 C55H74N9O16 11 16.5; found [M+H] + 1116.6.
- HTK03041 the HPLC conditions were 31 % acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 7.2 min.
- ESI-MS calculated [M+H] + for HTK03041 C53H74N9O16 1092.5; found [M+H] + 1092.6.
- HTK03024, HTK03055, HTK03056, HTK03058, HTK03082, HTK03085, HTK03086, HTK03087, HTK03089, and HTK03090 [00139] The structures of HTK03024, HTK03055, HTK03056, HTK03058, HTK03085, HTK03086, HTK03087, HTK03089, and HTK03090 are shown below:
- R I (HTK03024), CI (HTK03055), H (HTK03056), Br (HTK03058), F (HTK03085), OCH 3 (HTK03086), NH 2 (HTK03087), N0 2 (HTK03089), or CH 3 (HTK03090).
- Fmoc-Lys(ivDde)-Wang resin (0.3 mmol, 0.61 mmol/g loading) was suspended in DMF for 30 min. Fmoc was then removed by treating the resin with 20% piperidine in DMF (3 x 8 min). The isocyanate derivative of di-f-butyl ester of glutamate (3 eq.) was prepared according to literature procedures, 17 and added to the lysine-immobilized resin and reacted for 16 h. After washing the resin with DMF, the ivDde-protecting group was removed with 2% hydrazine in DMF (5 x 5 min).
- Fmoc-2- Nal-OH was then coupled to the side chain of Lys followed by Fmoc-tranexamic acid, Fmoc- Lys(ivDde)-OH, and Fmoc-Gly-OH via solid-phase peptide synthesis using Fmoc-based chemistry. All couplings were carried out in DMF using Fmoc-protected amino acid (3 eq.), HBTU (3 eq.), HOBT (3 eq.), and DIEA (8 eq.).
- the peptide was then deprotected and simultaneously cleaved from the resin by treating with 95/5 trifluoroacetic acid (TFA)/triisopropylsilane (TIS) for 2 h at room temperature. After filtration, the peptide was precipitated by the addition of cold diethyl ether to the TFA solution. The crude peptide was purified by HPLC using the semi-preparative column. The eluates containing the desired peptide were collected, pooled, and lyophilized. For HTK03024, the HPLC conditions were 37% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 8.8 min.
- ESI-MS calculated [M+H] + for HTK03024 C67H96N12O19I 1499.6; found [M+H] + 1499.6.
- HTK03055 the HPLC conditions were 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.7 min.
- ESI-MS calculated [M+H] + for HTK03055 C67H96N12O19CI 1407.7; found [M+H] + 1407.7.
- the HPLC conditions were 0-80% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min in 20 min.
- ESI-MS calculated [M+H] + for HTK03082 C66H95N12O19 1359.7; found [M+H] + 1359.9.
- HTK03085 the HPLC conditions were 34% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.0 min.
- ESI-MS calculated [M+H] + for HTK03085 C67H96N12O19F 1391.7; found [M+H] + 1391.9.
- HTK03086 the HPLC conditions were 33% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.1 min.
- ESI-MS calculated [M+H] + for HTK03086 C68H99N12O20 1403.7; found [M+H] + 1404.1.
- HTK03087 the HPLC conditions were 23% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 13.9 min.
- ESI-MS calculated [M+H] + for HTK03087 C67H98N13O19 1388.7; found [M+H] + 1389.0.
- HTK03089 the HPLC conditions were 33% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.6 min.
- ESI-MS calculated [M+H] + for HTK03089 C67H96N13O21 1418.7; found [M+H] + 1419.0.
- HTK03090 the HPLC conditions were 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.1 min.
- ESI-MS calculated [M+H] + for HTK03090 C68H99N12O19 1387.7; found [M+H] + 1387.9.
- Ga-labeled standards a solution of each precursor was incubated with GaC (5 eq.) in NaOAc buffer (0.1 M, 500 ⁇ , pH 4.2) at 80 °C for 15 min. The reaction mixture was then purified by HPLC using the semi-preparative column, and the HPLC eluates containing the desired peptide were collected, pooled, and lyophilized.
- the HPLC conditions were 27% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.4 min.
- ESI-MS calculated [M+H] + for Ga-HTK03026 C44H 7 3N 9 Oi6Ga 1052.4; found [M+H] + 1052.5.
- the HPLC conditions were 32% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.5 min.
- ESI-MS calculated [M+H] + for Ga-HTK03027
- ESI-MS calculated [M+H] + for Ga-HTK03041 1 159.4; found [M+H] + 1 159.4.
- the HPLC conditions were 39% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 8.0 min.
- ESI-MS calculated [M+H] + for Ga-HTK03024 C 67 H9 3 Ni20i9lGa 1565.5; found [M+H] + 1565.5.
- the HPLC conditions were 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min.
- ESI- MS calculated [M+H] + for Ga-HTK03055 C 67 H9 4 Ni 2 0igCIGa 1474.6; found [M+H] 2+ 738.4.
- the HPLC conditions were 34% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min.
- the retention time was 9.0 min.
- ESI-MS calculated [M+H] + for Ga-HTK03056 C6 7 Hg 4 Ni 2 0igGa 1439.6; found [M+H] + 1439.8.
- the HPLC conditions were 34% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.3 min.
- ESI-MS calculated [M+H] + for Ga-HTK03058 1517.5; found [M+H] + 1518.0.
- the HPLC conditions were 31 % acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 12.5 min.
- ESI-MS calculated [M+H] + for Ga-HTK03082 1426.6; found [M+H] + 1426.9.
- Ga-HTK03085 the HPLC conditions were 34% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 9.0 min.
- ESI-MS calculated [M+H] + for Ga-HTK03085 C 67 Hg 4 Ni20igFGa 1458.6; found [M+H] + 1459.6.
- the HPLC conditions were 33% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 10.7 min.
- ESI-MS calculated [M+H] + for Ga-HTK03089 C 67 H94Ni 3 02iGa 1485.6; found [M+H] + 1485.9.
- the HPLC conditions were 35% acetonitrile in water with 0.1 % TFA at a flow rate of 4.5 mL/min. The retention time was 11.3 min.
- ESI-MS calculated [M+H] + for Ga-HTK03090 C 6 8H9 7 Ni20i9Ga 1454.6; found [M+H] + 1455.8.
- LNCap cell line was obtained from ATCC (LNCaP clone FGC, CRL-1740). It was established from a metastatic site of left supraclavicular lymph node of human prostatic adenocarcinoma. Cells were cultured in PRM1 1640 medium supplemented with 10 % FBS, penicillin (100 U/mL) and streptomycin (100 ⁇ / ⁇ ) at 37 °C in a humidified incubator containing 5% CO2. Cells grown to 80-90% confluence were then washed with sterile phosphate-buffered saline (1 ⁇ PBS pH 7.4) and trypsinization. The collected cells number was counted with a Hausser Scientific (Horsham, PA) Hemacytometer.
- Imaging and biodistribution experiments were performed using NODSCID 1 L2RvKO male mice. Mice were anesthetized by inhalation with 2% isoflurane in oxygen, and implanted subcutaneously with 1 ⁇ 10 7 LNCaP cells behind left shoulder. Mice were imaged or used in biodistribution studies when the tumor grew up to reach 5-8 mm in diameter during 5-6 weeks.
- PET imaging experiments were conducted using Siemens Inveon micro PET/CT scanner. Each tumor bearing mouse was injected 6 - 8 MBq of 68Ga-labeled tracer through the tail vein under anesthesia (2% isoflurane in oxygen). The mice were allowed to recover and roam freely in their cage. After 50 min, the mice were sedated again with 2% isoflurane in oxygen inhalation and positioned in the scanner. A 10-min CT scan was conducted first for localization and attenuation correction after segmentation for reconstructing the PET images. Then, a 10-min static PET imaging was performed to determined uptake in tumor and other organs. The mice were kept warm by a heating pad during acquisition.
- mice were placed in the micro PET/CT scanner at 170 min p.i. Then, the CT acquisitions were conducted as described above, a 15-min static PET imaging was performed to determined uptake in tumor and other organs.
- mice were injected with the radiotracer as described above. At predetermined time points (1 or 3 h), the mice was anesthetized with 2% isoflurane inhalation, and euthanized by CO2 inhalation. Blood was withdrawn immediately from the heart, and the organs/tissues of interest were collected. The collected organs/tissues were weighed and counted using an automatic gamma counter. The uptake in each organ/tissue was normalized to the injected dose using a standard curve, and expressed as the percentage of the injected dose per gram of tissue (%ID/g).
- Table 8 Biodistribution data and tumor-to-background contrast ratios of 68 Ga- labeled HTK03089 and HTK03090 in mice bearing PSMA-expressing LNCAP cancer xenografts.
- Ga-HTK03024 es Ga-HTK03058 6e Ga-HTK03055 es Ga-HTK03056
- Kidneys 9.1 1 + 1.06 12.3 + 0.86 14.7 + 2 .13 17.5 ⁇ 3.83 31.1 + 4.40 35.6 + 7.23 123 ⁇ 30.4 31.1 + 15.2
- Table 10 Biodistribution data and tumor-to-background contrast ratios of 68Ga-labeled HTK03082, HTK03085, HTK03086, and HTK03087 in mice bearing PSMA-expressing LNCAP cancer xenografts.
- Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 749-753.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020207014223A KR20200100043A (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
EP18868855.0A EP3700917A4 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
AU2018352731A AU2018352731B2 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
CN201880081367.7A CN111630059A (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for the diagnosis or treatment of cancers expressing prostate specific membrane antigen |
CA3079906A CA3079906A1 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
JP2020543658A JP7282792B2 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for the diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
US16/758,361 US20200339625A1 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
JP2023081323A JP2023113695A (en) | 2017-10-22 | 2023-05-17 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
US18/219,458 US20230348535A1 (en) | 2017-10-22 | 2023-07-07 | Radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762575460P | 2017-10-22 | 2017-10-22 | |
US62/575,460 | 2017-10-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/758,361 A-371-Of-International US20200339625A1 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
US202217990897A Continuation | 2017-10-22 | 2022-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019075583A1 true WO2019075583A1 (en) | 2019-04-25 |
Family
ID=66173073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2018/051336 WO2019075583A1 (en) | 2017-10-22 | 2018-10-22 | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
Country Status (8)
Country | Link |
---|---|
US (2) | US20200339625A1 (en) |
EP (1) | EP3700917A4 (en) |
JP (2) | JP7282792B2 (en) |
KR (1) | KR20200100043A (en) |
CN (1) | CN111630059A (en) |
AU (1) | AU2018352731B2 (en) |
CA (1) | CA3079906A1 (en) |
WO (1) | WO2019075583A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110317151A (en) * | 2019-06-06 | 2019-10-11 | 原子高科股份有限公司 | Prostate cancer PET diagnostic reagent68Ga-HBBED-ANCP-PSMA and its preparation method and application |
WO2020210909A1 (en) * | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
WO2020252598A1 (en) * | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
WO2021177390A1 (en) | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | Compound and radioactive labeling compound |
WO2022186311A1 (en) | 2021-03-04 | 2022-09-09 | 日本メジフィジックス株式会社 | Compound and radioactive labeling compound |
CN116730983A (en) * | 2023-08-10 | 2023-09-12 | 山东大学 | Compound targeting prostate specific antigen and preparation method and application thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113372285B (en) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | Prostate specific membrane antigen inhibitor, radionuclide marker, preparation method and application thereof |
EP4400505A1 (en) * | 2021-09-03 | 2024-07-17 | Bivision Pharmaceuticals, Inc | Peptide-urea derivative, pharmaceutical composition containing same and application thereof |
AU2022384375A1 (en) * | 2021-11-10 | 2024-05-09 | Suzhou Ruihe Medicine Technology Co., Ltd | Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
TW202410923A (en) * | 2022-09-09 | 2024-03-16 | 大陸商同宜醫藥(蘇州)有限公司 | Radionuclide-drug conjugate and pharmaceutical composition and use thereof |
CN116217505A (en) * | 2023-03-17 | 2023-06-06 | 南京医科大学 | Novel marker targeting agents for diagnosis or treatment of cancers expressing prostate specific membrane antigen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10882871B2 (en) * | 2016-01-10 | 2021-01-05 | British Columbia Cancer Agency Branch | 18/19F-labelled compounds which target the prostate specific membrane antigen |
WO2018098390A1 (en) | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
CN110740757B (en) * | 2017-05-24 | 2023-04-04 | 同位素技术慕尼黑公司 | Novel PSMA-binding agents and uses thereof |
-
2018
- 2018-10-22 US US16/758,361 patent/US20200339625A1/en not_active Abandoned
- 2018-10-22 CN CN201880081367.7A patent/CN111630059A/en active Pending
- 2018-10-22 JP JP2020543658A patent/JP7282792B2/en active Active
- 2018-10-22 CA CA3079906A patent/CA3079906A1/en active Pending
- 2018-10-22 WO PCT/CA2018/051336 patent/WO2019075583A1/en unknown
- 2018-10-22 AU AU2018352731A patent/AU2018352731B2/en active Active
- 2018-10-22 KR KR1020207014223A patent/KR20200100043A/en not_active Application Discontinuation
- 2018-10-22 EP EP18868855.0A patent/EP3700917A4/en active Pending
-
2023
- 2023-05-17 JP JP2023081323A patent/JP2023113695A/en active Pending
- 2023-07-07 US US18/219,458 patent/US20230348535A1/en active Pending
Non-Patent Citations (4)
Title |
---|
KUO ET AL.: "A 177 Lu-labeled albumin-binder-conjugated PSMA-617 derivative with greatly enhanced radiation dose delivered to LNCaP tumor xenografts", J. NUCL. MED., vol. 59, no. 1, 1 May 2018 (2018-05-01), pages 7, XP009520414 * |
KUO ET AL.: "Enhancing Treatment efficacy of 177Lu-PSMA-617 with the conjugation of an Albumin-binding motif: Preclinical dosimetry and endoradiotherapy studies", MOL. PHARMACEUTICS, vol. 15, 2018, pages 5183 - 5191, XP055594872 * |
UMBRICHT ET AL.: "Preclinical development of novel PSMA-targeting radioligands: Modulation of albumin-binding properties to improve prostate cancer therapy", MOL. PHARMACEUTICS, vol. 15, 2018, pages 2297 - 2306, XP055594875 * |
WIRTZ ET AL.: "Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity", EJNMMI RESEARCH, vol. 8, 84, 2018, XP021259926 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020210909A1 (en) * | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
CN110317151A (en) * | 2019-06-06 | 2019-10-11 | 原子高科股份有限公司 | Prostate cancer PET diagnostic reagent68Ga-HBBED-ANCP-PSMA and its preparation method and application |
CN110317151B (en) * | 2019-06-06 | 2022-06-24 | 原子高科股份有限公司 | Prostate cancer PET diagnostic reagent68Ga-HBBED-ANCP-PSMA and preparation method and application thereof |
US11504441B2 (en) | 2019-06-21 | 2022-11-22 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
WO2020252598A1 (en) * | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
CN114401947A (en) * | 2019-06-21 | 2022-04-26 | 省卫生服务机构 | Radiolabeled compounds targeting prostate specific membrane antigen |
WO2021177390A1 (en) | 2020-03-04 | 2021-09-10 | 日本メジフィジックス株式会社 | Compound and radioactive labeling compound |
CN115210240A (en) * | 2020-03-04 | 2022-10-18 | 日本医事物理股份有限公司 | Compound and radiolabeled compound |
KR20220148811A (en) | 2020-03-04 | 2022-11-07 | 니혼 메디피직스 가부시키가이샤 | Compounds and radiolabeled compounds |
WO2022186311A1 (en) | 2021-03-04 | 2022-09-09 | 日本メジフィジックス株式会社 | Compound and radioactive labeling compound |
KR20230154183A (en) | 2021-03-04 | 2023-11-07 | 니혼 메디피직스 가부시키가이샤 | Compounds and Radiolabeled Compounds |
EP4303213A4 (en) * | 2021-03-04 | 2024-09-18 | Nihon Mediphysics Co Ltd | Compound and radioactive labeling compound |
CN116730983A (en) * | 2023-08-10 | 2023-09-12 | 山东大学 | Compound targeting prostate specific antigen and preparation method and application thereof |
CN116730983B (en) * | 2023-08-10 | 2023-11-03 | 山东大学 | Compound targeting prostate specific antigen and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2018352731B2 (en) | 2023-10-05 |
US20200339625A1 (en) | 2020-10-29 |
EP3700917A4 (en) | 2021-08-04 |
JP7282792B2 (en) | 2023-05-29 |
JP2023113695A (en) | 2023-08-16 |
US20230348535A1 (en) | 2023-11-02 |
CN111630059A (en) | 2020-09-04 |
EP3700917A1 (en) | 2020-09-02 |
CA3079906A1 (en) | 2019-04-25 |
JP2021503490A (en) | 2021-02-12 |
KR20200100043A (en) | 2020-08-25 |
AU2018352731A1 (en) | 2020-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018352731B2 (en) | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer | |
US11951190B2 (en) | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | |
JP6814234B2 (en) | 177-Lu labeled peptide for site-specific uPAR targeting | |
Lane et al. | Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists,[64Cu-NO2A-(X)-BBN (7–14) NH2], in a prostate tumor xenografted mouse model | |
EP3766893B1 (en) | 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen | |
Nanda et al. | Bombesin analogues for gastrin-releasing peptide receptor imaging | |
US20220233726A1 (en) | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer | |
US20230105344A1 (en) | Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers | |
US20220133919A1 (en) | ONE STEP 64Cu-BaBaSar-RGD2 PRODUCTION METHOD | |
Okarvi et al. | Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics | |
Lee et al. | Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy | |
Prasanphanich et al. | The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals | |
Kim et al. | Evaluation of a 64Cu-labeled 1, 4, 7-triazacyclononane, 1-glutaric acid-4, 7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model | |
JP2005514335A (en) | PACAP compositions and methods for tumor imaging and therapy | |
Giblin et al. | In vitro and in vivo evaluation of 111 In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers | |
WO2024153756A1 (en) | Radionuclide labelled peptide conjugate for site-specific upar-targeting | |
CN118159305A (en) | Radioactive complexes and radiopharmaceuticals of deglycosylated antibodies | |
Bugaj | Octreotate: a new Somatostatin analogue for tumor imaging and radionuclide therapy | |
JP2015083546A (en) | Radioactive labeling agent for inspection/therapy of cancer primary focus/bone metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18868855 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3079906 Country of ref document: CA Ref document number: 2020543658 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018352731 Country of ref document: AU Date of ref document: 20181022 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018868855 Country of ref document: EP Effective date: 20200525 |